Oncoinvent ASA (0RU5.L)

Name: Oncoinvent ASA Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2026-05-25

Latest Quarter

2026-05-25

Revenue

$4.7M

Net Income

-$54.1M

Operating Margin

-1,155.6%

Free Cash Flow

-$153M

Debt / Assets

21.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Oncoinvent ASA (0RU5.L).
Income Statement (Quarterly)	2026-05-25	2025-06-30	2025-03-31	2024-12-31
Revenue	4,724,000	4,724,000	2,362,000	681,000
Cost of Revenue	0	0	0	105,000
Gross Profit	4,724,000	4,724,000	2,362,000	576,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	10,335,000	10,335,000	5,167,500	21,069,000
Operating Expenses	59,313,000	59,313,000	29,656,500	61,392,000
Operating Income	-54,589,000	-54,589,000	-27,294,500	-60,711,000
Interest Expense	0	0	0	2,634,000
Income Before Tax	-54,139,000	-54,139,000	-27,069,500	-53,444,000
Income Tax Expense	0	0	0	0
Net Income	-54,139,000	-54,139,000	-27,069,500	-53,444,000
Per Share
EPS	-1.38	-1.38	-0.69	-1.36
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Oncoinvent ASA (0RU5.L).
Income Statement (Annual)	2024-12-31	2023-12-31	2022-12-31
Revenue	848,000	354,000	389,000
Cost of Revenue	0	0	0
Gross Profit	848,000	354,000	389,000
Operating Expenses
R&D Expenses	0	0	0
SG&A Expenses	38,501,000	84,387,000	105,057,000
Operating Expenses	152,082,000	192,173,000	315,561,000
Operating Income	-151,234,000	-191,819,000	-316,055,000
Interest Expense	4,700,000	578,000	11,514,000
Income Before Tax	-139,282,000	-190,401,000	-302,122,000
Income Tax Expense	0	0	0
Net Income	-139,282,000	-190,401,000	-302,122,000
Per Share
EPS	-3.95	-13.30	-0.39
EPS Diluted	0.00	0.00	0.00

Balance sheet quarterly history for Oncoinvent ASA (0RU5.L).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	140,155,000	155,969,000	150,804,000
Short Term Investments	0	452,000	0
Net Receivables	679,000	0	680,000
Inventory	0	0	0
Total Current Assets	154,543,000	173,904,000	166,663,000
Property Plant Equipment	1,254,000	431,000	43,000
Goodwill and Intangibles	0	0	0
Total Assets	155,796,000	174,335,000	166,706,000
Liabilities
Account Payables	12,924,000	18,605,000	29,634,000
Short Term Debt	884,000	418,000	0
Total Current Liabilities	32,277,000	46,859,000	77,933,000
Long Term Debt	818,000	0	275,000
Total Liabilities	33,095,000	46,859,000	78,208,000
Shareholders Equity
Retained Earnings	22,019,000	-189,234,000	0
Total Shareholders Equity	122,701,000	127,476,000	88,498,000

Balance sheet annual history for Oncoinvent ASA (0RU5.L).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	140,155,000	155,969,000	150,804,000
Short Term Investments	0	452,000	0
Net Receivables	679,000	0	680,000
Inventory	0	0	0
Total Current Assets	154,543,000	173,904,000	166,663,000
Property Plant Equipment	1,254,000	431,000	43,000
Goodwill and Intangibles	0	0	0
Total Assets	155,796,000	174,335,000	166,706,000
Liabilities
Account Payables	12,924,000	18,605,000	29,634,000
Short Term Debt	884,000	418,000	0
Total Current Liabilities	32,277,000	46,859,000	77,933,000
Long Term Debt	818,000	0	275,000
Total Liabilities	33,095,000	46,859,000	78,208,000
Shareholders Equity
Retained Earnings	22,019,000	-189,234,000	0
Total Shareholders Equity	122,701,000	127,476,000	88,498,000

Cash flow quarterly history for Oncoinvent ASA (0RU5.L).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-139,282,000	-190,401,000	-302,122,000
Depreciation & Amortization	456,000	223,000	883,000
Stock Based Compensation	5,709,000	3,135,000	3,466,000
Change in Working Capital	-11,636,000	-33,389,000	10,179,000
Operating Cash Flow	-153,242,000	-225,101,000	-285,282,000
Investing Activities
Capital Expenditure	0	0	0
Investments	0	0	0
Investing Cash Flow	3,688,000	3,055,000	299,000
Financing Activities
Debt Repayment	-438,000	0	-307,000
Common Stock Issued/Repurchased	138,874,000	262,048,000	3,211,000
Dividends Paid	0	0	0
Financing Cash Flow	129,610,000	224,884,000	2,904,000
Summary
Free Cash Flow	-153,242,000	-225,101,000	-285,282,000
Net Change in Cash	-16,266,000	5,618,000	-285,842,000

Cash flow annual history for Oncoinvent ASA (0RU5.L).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-139,282,000	-190,401,000	-302,122,000
Depreciation & Amortization	456,000	223,000	883,000
Stock Based Compensation	5,709,000	3,135,000	3,466,000
Change in Working Capital	-11,636,000	-33,389,000	10,179,000
Operating Cash Flow	-153,242,000	-225,101,000	-285,282,000
Investing Activities
Capital Expenditure	0	0	0
Investments	0	0	0
Investing Cash Flow	3,688,000	3,055,000	299,000
Financing Activities
Debt Repayment	-438,000	0	-307,000
Common Stock Issued/Repurchased	138,874,000	262,048,000	3,211,000
Dividends Paid	0	0	0
Financing Cash Flow	129,610,000	224,884,000	2,904,000
Summary
Free Cash Flow	-153,242,000	-225,101,000	-285,282,000
Net Change in Cash	-16,266,000	5,618,000	-285,842,000